In vitro activity of Tedizolid and Dalbavancin against MRSA strains is dependent on infection source

Abstract

Objective: We tested the in vitro susceptibility to Tedizolid and Dalbavancin of Methicillin-resistant Staphylococcus aureus strains recovered from blood and wound cultures, and compared our results with studies conducted in the last four years. We examined whether the spa types affect the susceptibility of the different strains. Methods: We analyzed 275 Methicillin-resistant S. aureus strains recovered from 128 blood and 147 wound samples. For each strain, we performed minimum inhibitory concentration for Tedizolid and Dalbavancin and spa typing. We also performed a non-systematic review of the worldwide literature from the last four years concerning the in vitro activity of Tedizolid and Dalbavancin using the PubMed database; results were restricted by Results: We found one Dalbavancin-resistant isolate (0.36%) and no resistance to Tedizolid. The minimum inhibitory concentration values were dependent in the strain source (wound vs. blood) for both antibiotics. For Dalbavancin, there was also dependence on the spa type. Conclusion: This study indicates Tedizolid and Dalbavancin have potent in vitro activity against the prevalent S. aureus clones in Israel. Further studies should be performed in order to uncover the factors contributing to reduced susceptibility of S. aureus strains to new drugs.

Recent Advances in the Development of Semisynthetic Glycopeptide Antibiotics: 2014–2022

“… 100 Dalbavancin exhibits potent activity toward Gram-positive strains, including MRSA (MIC = 0.06–1 μg/mL), streptococci (MIC ≤0.03 μg/mL), and VanB-type VRE (MIC ≤0.03–4 μg/mL). 52 , 101 − 104 …”

“…Dalba­vancin is synthesized from A40926 by a three-step sequence, resulting in amidation of the C-terminus with 3-(dimethyl­amino)-1-propyl­amine . Dalba­vancin exhibits potent activity toward Gram-positive strains, including MRSA (MIC = 0.06–1 μg/mL), strepto­cocci (MIC ≤0.03 μg/mL), and VanB-type VRE (MIC ≤0.03–4 μg/mL). ,− …”

Dual-Drug Delivery via Zein In Situ Forming Implants Augmented with Titanium-Doped Bioactive Glass for Bone Regeneration: Preparation, In Vitro Characterization, and In Vivo Evaluation

“…As an approach to potentiate the therapeutic usefulness of the prepared implants, tedizolid phosphate was added to the chosen implant (BG-ZIFI 5) to treat associated infections [71]. It is a potent antibacterial pro-drug that is approved for its efficacy against methicillin-resistant staphylococcus aureus and acts by inhibiting the bacterial protein synthesis via binding to the 50S ribosomal subunit [72,73]. It is activated in vivo to its active metabolite (tedizolid) by the action of esterase enzymes such as alkaline phosphatase (ALP), which is produced naturally during the bone formation process [74].…”